



## Joint association of alcohol consumption and adiposity with alcohol- and obesity-related cancer in a population sample of 399,575 UK adults

Elif Inan-Eroglu<sup>1,2\*</sup>, Bo-Huei Huang<sup>1</sup>, Peter Sarich<sup>3</sup>, Natasha Nassar<sup>4</sup> and Emmanuel Stamatakis<sup>1</sup>

<sup>1</sup>Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

<sup>2</sup>Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Germany

<sup>3</sup>The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW, Australia

<sup>4</sup>Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW, Australia

(Submitted 1 May 2022 – Final revision received 14 October 2022 – Accepted 18 October 2022 – First published online 21 October 2022)

### Abstract

Obesity and alcohol consumption are both important modifiable risk factors for cancer. We examined the joint association of adiposity and alcohol consumption with alcohol- and obesity-related cancer incidence. This prospective cohort study included cancer-free UK Biobank participants aged 40–69 years. Alcohol consumption was categorised based on current UK guidelines into four groups. We defined three markers of adiposity: body fat percentage (BF %), waist circumference and BMI and categorised each into three groups. We derived a joint alcohol consumption and adiposity marker variable with twelve mutually exclusive categories. Among 399 575 participants, 17 617 developed alcohol-related cancer and 20 214 developed obesity-related cancer over an average follow-up of 11·8 (SD 0·9) years. We found relatively weak evidence of independent associations of alcohol consumption with cancer outcomes. However, the joint association analyses showed that across all adiposity markers, above guideline drinkers who were in the top two adiposity groups had elevated cancer incidence risk (e.g. HR for alcohol-related cancer was 1·53 (95 % CI (1·24, 1·90)) for within guideline drinkers and 1·61 (95 % CI (1·30, 2·00)) for above guideline drinkers among participants who were in the top tertile BF %. Regardless of alcohol consumption status, the risk of obesity-related cancer increased with higher adiposity in a dose–response manner within alcohol consumption categories. Our study provides guidance for public health priorities aimed at lowering population cancer risk via two key modifiable risk factors.

**Key words:** Cancer: Alcohol consumption: Adiposity: Obesity

Cancer constitutes the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020<sup>(1)</sup>. There is overwhelming evidence that lifestyle risk factors impact cancer risk and that population-wide changes can significantly reduce cancer burden<sup>(2)</sup>. Owing to the impact of modifiable risk factors, especially for the most prevalent cancers, more than half of cancers occurring today may be preventable<sup>(3)</sup>. Among the key modifiable risk factors for cancer are alcohol consumption and adiposity<sup>(4)</sup>.

Alcohol is classified as a Group 1 carcinogen (highest level) by the International Agency for Research on Cancer (IARC)<sup>(5)</sup> and has been strongly linked to many common cancer incidence and mortality<sup>(6–8)</sup>. Globally, 4·1 % (741 300 cases) of all new cancer cases in 2020 were attributable to alcohol consumption<sup>(8)</sup>. Although current evidence suggests that the safest level of alcohol consumption is total avoidance<sup>(9)</sup>, alcohol consumption has

been rising in many countries<sup>(10,11)</sup>. Adiposity is also another major contributor to cancer risk with a dramatic rise in prevalence of obesity worldwide<sup>(12,13)</sup>. A review on human, animal and mechanistic studies conducted by IARC showed that overweight or obesity increases the risk of at least thirteen types of cancer that accounted for 42 % of all new cancer diagnoses worldwide<sup>(14)</sup>.

Although alcohol consumption and adiposity have been separately investigated as cancer risk factors<sup>(15–18)</sup>, very few studies have investigated the joint association between alcohol consumption and adiposity with cancer risk<sup>(19–21)</sup>. Loomba *et al.*<sup>(20)</sup> showed that body mass index (BMI) defined obesity and alcohol have synergistic effects of increasing the risk of hepatocellular carcinoma. In a study of colorectal cancer risk<sup>(21)</sup>, alcohol was associated with a higher risk among obese participants (BMI ≥ 30 kg/m<sup>2</sup>). Most of these studies focused on a

**Abbreviations:** ICD, International Classification of Diseases; IARC, International Agency for Research on Cancer; WC, waist circumference; BF %, body fat percentage.

\* **Corresponding author:** Dr E. Inan-Eroglu, email [elif.inaneroглу@sydney.edu.au](mailto:elif.inaneroглу@sydney.edu.au)



single cancer site<sup>(19,20)</sup> or were retrospective case–control studies<sup>(21)</sup>. Additionally, the majority of studies focused on BMI<sup>(19–21)</sup>. No study has examined the association of alcohol and excess adiposity on the full range of cancers that are known to be influenced by alcohol intake and obesity.

The aim of this study was to investigate the joint association of excess adiposity and alcohol on alcohol-related, obesity-related and total cancer incidence in a large population sample of UK adults with no cancer diagnosis at baseline.

## Methods

### Study population

This research was conducted using the UK Biobank, a population-based prospective cohort study. About 9.2 million invitations were mailed to recruit participants aged 40–69 years between 2006 and 2010 from twenty-two centres across the UK<sup>(22)</sup>. This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the National Health Service (NHS), National Research Ethics Service (Ref 11/NW/0382). Written informed consent was obtained from all subjects.

We excluded participants with missing data on any exposures or covariates. We also excluded participants with a baseline diagnosis of cancer (International Classification of Diseases, Tenth Revision (ICD-10), C00.0 to C97) and underweight participants (BMI < 18.5 kg/m<sup>2</sup>) from all analyses to reduce the possibility of confounding by poor health status-related weight loss (online Supplementary Table 1)<sup>(23)</sup>.

### Alcohol consumption and adiposity

Alcohol consumption was self-reported as the number of UK units per week (average weekly intake of red wine + champagne and white wine + beer and cider + spirits + fortified wine + and other). In the UK, one unit is equal to 8 g of ethanol. Participants were grouped based on the current UK alcohol guidelines<sup>(24)</sup>: (1) never drinkers; (2) previous drinkers; (3) within guideline drinkers ( $\leq 14$  UK units of alcohol/week); and (4) above guideline drinkers ( $> 14$  UK units)<sup>(25)</sup>. Previous drinkers included participants who stopped drinking due to illness or ill health (23.5 %), doctor's advice (5.2 %), health precaution (19.8 %), financial or other reasons (1.8 %) and other reasons (49.7 %). Never drinkers included participants who never drank alcohol in their lifetime.

Adiposity was defined using measures of body fat percentage (BF %), waist circumference (WC) and BMI. BF % was measured by bioimpedance using the Tanita BC-418MA device (Tanita). We categorised BF % based on the sex-specific tertiles of BF %. WC at the level of the umbilicus was measured by a trained professional using a Wessex non-stretchable sprung tape, with the participant in the resting-standing position. WC was categorised as: (1) normal (< 80 cm for women, < 94 cm for men); (2) increased risk of metabolic complications (80–88 cm for women, 94–102 cm for men); and (3) substantially increased risk of metabolic complications (> 88 cm for women, > 102 cm for men)<sup>(26)</sup>. Trained staff measured body weight and height, and BMI was

calculated as weight (in kilograms) divided by height squared (in metres). For the analyses, individuals were categorised into three groups: (1) normal weight (18.5–24.9 kg/m<sup>2</sup>); (2) overweight (25.0–29.9 kg/m<sup>2</sup>); and (3) obese ( $\geq 30.0$  kg/m<sup>2</sup>).

For the joint alcohol consumption and adiposity marker analyses, we combined the four alcohol consumption and three adiposity marker categories to create a variable with twelve mutually exclusive categories.

## Outcomes

We identified alcohol- and obesity-related cancers from hospital admissions and cancer registry data. These were coded according to the International Classification of Diseases 9th (ICD-9)<sup>(27)</sup> and 10th Revision (ICD-10)<sup>(28)</sup> diagnosis codes (listed in the Appendix). Hospital admission data were censored in March 2020 for England and Scotland and February 2018 for Wales. Cancer registry data were censored in July 2019 for England and Scotland and October 2015 for Wales. Participants were followed up from the date of attendance at the recruitment centre to the date of cancer incidence or date of censorship, whichever came first. Cancer registry data were obtained from the National Health Service (NHS) Information Centre (England and Wales) and the NHS Central Register Scotland (Scotland) and were linked to survey data. In line with a previous study<sup>(29)</sup>, we classified alcohol-related cancers using two definitions, depending on the strength of evidence for their causal relationship with alcohol in existing literature and IARC<sup>(6,30–33)</sup>:

- A narrow definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach and female breast cancer.
- A broader definition included all above plus pancreas and lung cancers, which have less consistent evidence of an association with alcohol.

Throughout the manuscript, alcohol-related cancer indicates the narrow definition, unless otherwise stated. We used IARC's definition for obesity-related cancers<sup>(14)</sup>, including oesophagus, gastric cardia, colorectal, liver, gallbladder, pancreas, female breast, corpus uteri, ovary, kidney, thyroid and multiple myeloma. We also combined alcohol-related and obesity-related cancer into one outcome (fifteen sites in total: oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach, female breast, gallbladder, pancreas, corpus uteri, ovary, kidney, thyroid and multiple myeloma) which we referred as 'combined cancers' in the text. In addition, we present results for cancers that are both obesity- and alcohol-related (five sites: oesophagus, liver, colorectal, gastric cardia and breast cancers). We refer to this outcome as 'overlapping cancers' throughout the text.

## Covariates

We adjusted analyses using information collected from baseline surveys, including age (years), sex, dietary pattern (calculated using information on consumption of fruit, vegetables, fish, unprocessed red meat and processed meat)<sup>(34–36)</sup>, education (college/university degree; higher school certificate or equivalent; school certificate or equivalent; secondary education



certificate or equivalent; vocational qualification, higher diploma/certificate, or equivalent; other professional qualifications), physical activity (International Physical Activity Questionnaire (IPAQ)<sup>(37)</sup> derived MET-hours per week), smoking (never, previous and current smokers), sleep duration (h/d), socio-economic status (Townsend Deprivation Index<sup>(38)</sup>) and chronic illness (the presence/absence of CVD (ICD-10 codes I00 to I99) or type 2 diabetes (E11.0 to E11.9 and E12) using self-reported doctor diagnosis and hospital admission records).

### Statistical analyses

We used Cox proportional hazard models to estimate associations of exposures and outcomes. We examined the proportional hazards assumption using Kaplan–Meier survival plots<sup>(39)</sup> and Schoenfeld residuals, and we noted no apparent violations ( $P > 0.05$  for the association of alcohol consumption and adiposity markers with cancer risk). Firstly, we examined the independent association of alcohol consumption and adiposity markers with all study outcomes, using never drinkers and the bottom group of each adiposity marker as referent groups, respectively. We then examined the joint association of adiposity and alcohol consumption with the incidence of alcohol-related, obesity-related and total cancers using the 'optimal' group of the joint variable as the referent group (never drinker and lowest adiposity marker group of each adiposity marker). The first model was adjusted for sex and baseline age. The second model was further adjusted for smoking, diet, education, sleep, socio-economic status and physical activity. The fully adjusted model also included chronic illness (CVD and type 2 diabetes). We also mutually adjusted for BMI and alcohol consumption in the independent effects of alcohol and adiposity analyses. We tested for statistical interaction by entering an alcohol consumption\*adiposity marker (BF %, WC or BMI) term in the first model. In a sensitivity analysis, we excluded events in the first 3 years of follow-up from analyses of the joint association between alcohol consumption and adiposity markers with obesity- and alcohol-related cancer incidence to minimise the possibility of reverse causation bias. We also examined the joint association between alcohol consumption and adiposity markers with incidence for each alcohol-related cancer site. As smoking and alcohol consumption can synergistically increase the risk of cancer<sup>(40)</sup>, we tested for a three-way statistical interaction for alcohol consumption\*adiposity marker (BF %, WC or BMI)\*smoking status in the first model. We then examined the joint association between smoking status and alcohol consumption with alcohol-related cancer incidence. For this analysis, we grouped smoking status as never, previous, and current smokers and derived a joint alcohol consumption and smoking status variable with twelve mutually exclusive categories. We used the 'optimal' group of the joint variable as the referent group (never drinker and never smoker group). All analyses were performed using R statistical software. We reported this study as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (Supplemental STROBE Checklist).

### Results

Table 1 shows the baseline characteristics of the sample ( $n$  399 575). The mean age was 56.2 (SD: 8.1) years, and 55 %

were females. Participants had an average BF % of 31.6 %, a WC of 90.4 cm and a BMI of 27.5 kg/m<sup>2</sup>. Over an average follow-up time of 11.8 (0.9) years a total of 61 898 incident cancer events were identified, including 22 211/17 616 alcohol-related (broad/narrow definition), and 20 214 obesity-related cancer events. We found an interaction effect between alcohol consumption and WC ( $P = 0.015$ ) and BMI ( $P = 0.002$ ) for broad definition of alcohol-related cancer and total cancer ( $P < 0.001$  for both adiposity markers) (online Supplementary Table 1).

### Independent association of the exposures

Compared with the bottom % BF tertile, both middle and top tertiles showed increased risk across all cancer outcomes except total cancer, with no evidence of dose–response (online Supplementary Table 2). We found similar association between WC and BMI with cancer incidence (online Supplementary Tables 3 and 4). Alcohol consumption was associated with total cancer risk, but only above guideline drinking was associated with alcohol-related cancer risk. Current alcohol consumption was not associated with outcomes that included obesity-related cancer (online Supplementary Table 5).

### Joint association of alcohol and adiposity with incident cancer

**Body fat percentage.** Previous drinkers had the highest cancer risk across all analyses. Compared with the referent 'optimal' category (never drinker/bottom tertile BF %), most other groups had a higher risk of alcohol-related cancer (both narrow and broad definitions) (Fig. 1, online Supplementary Table 6). Participants in the middle and top BF % groups who drink within and above guideline levels had an elevated risk of alcohol-related cancers. Compared with the reference group, the risk of alcohol-related cancer for those in the top tertile BF % and within guideline drinkers was HR 1.53 (95 % CI (1.24, 1.90)) and for above guideline drinkers was HR 1.61 (95 % CI (1.30, 2.00)). The analysis of the joint association with the risk of combined cancers and overlapping cancers produced similar results (Fig. 1, online Supplementary Table 6). In addition, the risk of combined and overlapping cancers increased with elevated BF % in a dose–response manner.

Irrespective of alcohol consumption status, obesity-related cancer risk increased at higher BF % levels. Compared with the referent category, the top tertile BF % had higher risk of obesity-related cancer regardless of alcohol consumption. For example, never drinkers and above guideline drinkers who were in the top tertile BF % had a similar 39 % increased risk of obesity-related cancer (HR 1.39, 95 % CI (1.14, 1.71) and HR 1.39, 95 % CI (1.14, 1.68), respectively) (Fig. 1, online Supplementary Table 6). Alcohol consumption for all BF % categories was associated with total cancer incidence (online Supplementary Table 6).

**Waist circumference.** Risk for all cancer outcomes increased monotonically with elevated WC regardless of the level of alcohol consumption (Fig. 2, online Supplementary Table 7). For all WC groups, previous drinking was associated with alcohol-related cancer. In addition, among above guideline drinkers, participants with higher WC had a higher risk of alcohol-related

**Table 1.** Baseline characteristics of study sample by alcohol consumption category (*n* 399 575)

	Overall		Never drinker		Previous drinker		Within guidelines drinker		Above guidelines drinker	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Total <i>n</i>	399 575		17 061		13 648		224 171		144 695	
Weekly alcohol unit	13.7	16.6	–		–		5.1	4.6	30.0	17.6
Age	56.2	8.1	56.7	8.6	56.9	7.9	56.2	8.1	56.1	7.9
Male	179 944	45.0	4804	28.2	6031	44.2	76 234	34.0	92 875	64.2
Follow-up*	11.8	0.9	11.7	0.9	11.8	0.9	11.8	0.9	11.8	0.9
Sleep	7.2	1.1	7.1	1.3	7.1	1.4	7.2	1.1	7.2	1.0
Dietary pattern score (DPS)†	1.7	0.5	1.7	0.5	1.7	0.5	1.7	0.5	1.6	0.5
Chronic disease‡	169 133	42.3	8450	49.5	7178	52.6	90 256	40.3	63 249	43.7
Socio-economic status	–1.4	3.1	–0.2	3.5	–0.1	3.5	–1.4	3.0	–1.5	2.9
Smoking status										
Never	221 457	55.4	14 016	82.2	6162	45.1	138 492	61.8	62 787	43.4
Current	137 320	34.4	1999	11.7	5403	39.6	67 054	29.9	62 864	43.4
Previous	40 798	10.2	1046	6.1	2083	15.3	18 625	8.3	19 044	13.2
Physical activity§	251.9	226.8	218.8	225.5	236.0	233.9	246.7	225.9	265.2	226.9
Body fat percentage (BF %)¶	31.6	8.5	34.7	8.8	32.8	9.2	32.8	8.6	29.3	7.7
BMI¶	27.5	4.8	28.3	5.5	28.5	5.7	27.4	5.0	27.4	4.2
Waist circumference (WC) (cm)**	90.4	13.4	90.4	14.1	92.8	14.9	88.9	13.5	92.4	12.7
Narrow definition of alcohol-related cancer‡‡	17 616	4.4	742	4.3	691	5.1	10 172	4.5	6111	4.2
Broad definition of alcohol-related cancer‡‡	22 211	5.6	922	5.4	966	7.1	12 362	5.5	7961	5.5
Obesity-related cancer§§	20 124	5.0	962	5.6	755	5.5	11 832	5.3	6575	4.5
Total cancer	61 898	15.5	2229	13.1	2215	16.2	33 362	14.9	24 092	16.7

\* Follow-up years until cancer incident or end of the study, whichever came first.

† DPS was determined by higher consumption of fruit, vegetables, and fish and lower consumption of processed meats and red meats (Rutten-Jacobs *et al.*, 2018).

‡ Major CVD (ICD-10 codes I00 to I99), type 2 diabetes (ICD-10 codes E11.0 to E11.9 and E12) and dyslipidaemia (ICD-10 codes E78.0–E78.6) diagnosed by a doctor and hospital admission records.

§ Physical activity (PA) patterns were based on the frequency and duration of PA in the 4 weeks prior to the survey. PA was quantified in Metabolic Equivalent Task (MET)-h/week, computed by multiplying the activity by the MET value and then summing the number of MET-hours spent performing each activity per week.

¶ BF % was measured by bioimpedance using the Tanita BC-418MA device (Tanita).

¶ BMI = Weight (kg)/height (m<sup>2</sup>).

\*\* Waist circumference were measured by using flexible plastic tape with the participant in the resting-standing position by a trained professional.

‡‡ Alcohol-related cancer according to the broad definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach, female breast, pancreas and lung cancer (IARC, 2014).

‡‡ Alcohol-related cancer according to the narrow definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach and female breast (IARC, 2014).

§§ Obesity-related cancer included meningioma, multiple myeloma, adenocarcinoma of the oesophagus, and cancers of the thyroid, postmenopausal breast, gallbladder, stomach, liver, pancreas, kidney, ovaries, uterus, colon and rectum (colorectal) (Lauby-Secretan *et al.*, 2016).

||| The definition of total cancer excludes *in situ*, benign, uncertain or non-well-defined cancers.


Alcohol consumption categories are based on the average weekly intake of standard drinks relative to UK guidelines. In the UK, one standard drink equals to 8 g of pure alcohol. Within guidelines: ≤ 14 units/week; above guidelines: >14 units/week.

cancer (HR 1.25, 95 % CI (1.08, 1.43)) for increased risk of WC and HR 1.34, 95 % CI (1.16, 1.54) for high risk of WC) compared with the referent optimal category (never drinker/normal WC). Higher WC was associated with obesity-related cancer independent from alcohol consumption status. However, the risk increased with higher alcohol consumption (HR 1.21, 95 % CI (1.04, 1.41) for never drinkers; HR 1.25, 95 % CI (1.11, 1.42) for within guideline drinkers and HR 1.28, 95 % CI (1.10, 1.51) and HR 1.28, 95 % CI (1.13, 1.45) for above guideline drinkers). We observed a similar pattern of results for obesity-related cancer, as well as combined and overlapping cancers (online Supplementary Table 7).

**BMI.** The joint association of various levels of alcohol consumption and BMI with cancer (Fig. 3 and online Supplementary Table 8) was less clear than other adiposity markers. Only above guideline drinkers who were overweight or obese had higher

alcohol-related cancer risk compared with the referent optimal group (HR 1.16, 95 % CI (1.01, 1.41) and HR 1.22, 95 % CI (1.05, 1.41), respectively). We also found that obesity was associated with a higher, but similar risk of obesity-related cancer among within guideline (HR 1.20, 95 % CI (1.05, 1.37)) and above guideline drinkers (HR 1.19, 95 % CI (1.04, 1.36)), with no evidence of dose–response. The joint association of alcohol consumption and BMI with risk of combined and overlapping cancer showed similar results. However, the point estimates were greater in overlapping cancer analyses than combined cancer analysis. For instance, above the guideline drinker and obese participants showed a slightly higher overlapping cancer risk (HR 1.25, 95 % CI (1.07, 1.45)) than combined cancer (HR 1.16, 95 % CI (1.02, 1.33)) (online Supplementary Table 8).

**Sensitivity analysis.** Exclusion of cases that occurred in the first 3 years of follow-up did not appreciably change the results for




**Fig. 1.** Joint associations between alcohol consumption and body fat percentage with cancer incidence ( $n$  399 575). Cox proportional hazard model. Never drinker | 1<sup>st</sup> T is the referent group. Model is adjusted for baseline age, sex, smoking status, dietary pattern score (determined by higher consumption of fruit, vegetables, and fish and lower consumption of processed meats and red meats (Rutten-Jacobs *et al.*, 2018)), sleep duration (h/night), education, Townsend Deprivation Index, physical activity ((MET)-hour/week) and chronic diseases (major CVD (ICD-10 codes I00 to I99), type 2 diabetes (ICD-10 codes E11.0 to E11.9 and E12) and dyslipidaemia (ICD-10 codes E78.0–E78.6) diagnosed by a doctor and hospital admission records and self-reported CVD and type 2 diabetes). Body fat percentage (BF %) was measured by bioimpedance using the Tanita BC-418MA device (Tanita). BF % by tertile: Tertile 1 (T1): <23.1 % for women and <33.9 % for men, Tertile 2 (T2): 23.1–27.8 % for women and 33.9–39.8 % for men, Tertile 3 (T3): >27.8 % for women and >39.8 % for men. Alcohol consumption categories are based on the average weekly intake of standard drinks relative to UK guidelines. In the UK, one standard drink equals to 8 g of pure alcohol. Within guidelines:  $\leq 14$  units/week; above guidelines:  $> 14$  units/week. Alcohol-related cancer according to the narrow definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach and female breast (IARC, 2014). Obesity-related cancer included meningioma, multiple myeloma, adenocarcinoma of the oesophagus, and cancers of the thyroid, postmenopausal breast, gallbladder, stomach, liver, pancreas, kidney, ovaries, uterus, colon and rectum (colorectal) (Lauby-Secretan *et al.*, 2016).

the joint association between alcohol consumption and adiposity markers with obesity- and alcohol-related cancer incidence (online Supplementary Table 9).

The joint association of alcohol consumption and adiposity markers with risk of each individual alcohol-related cancer site showed that participants who drink within guideline and above






**Fig. 2.** Joint associations between alcohol consumption and waist circumference with cancer incidence ( $n$  399 575). Cox proportional hazard model. Never drinker | Normal WC is the referent group. Model is adjusted for baseline age, sex, smoking status, dietary pattern score (determined by higher consumption of fruit, vegetables, and fish and lower consumption of processed meats and red meats (Rutten-Jacobs *et al.*, 2018)), sleep duration (h/night), education, Townsend Deprivation Index, physical activity ((MET)-hour/week) and chronic diseases (major CVD (ICD-10 codes I00 to I99), type 2 diabetes (ICD-10 codes E11.0 to E11.9 and E12) and dyslipidaemia (ICD-10 codes E78.0–E78.6) diagnosed by a doctor and hospital admission records and self-reported CVD and type 2 diabetes). Waist circumference were measured by using flexible plastic tape with the participant in the resting-standing position by a trained professional. WHO classification: normal (<80 cm for women, <94 cm for men), increased risk of metabolic complications (80–88 cm for women, 94–102 cm for men), substantially increased risk of metabolic complications (>88 cm for women, >102 cm for men). NWC: normal waist circumference; IWC: Increased risk waist circumference; HWC: high-risk waist circumference. Alcohol consumption categories are based on the average weekly intake of standard drinks relative to UK guidelines. In the UK, one standard drink equals to 8 g of pure alcohol. Within guidelines:  $\leq 14$  units/week; above guidelines:  $>14$  units/week. Alcohol-related cancer according to the narrow definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach and female breast (IARC, 2014). Obesity-related cancer included meningioma, multiple myeloma, adenocarcinoma of the oesophagus, and cancers of the thyroid, postmenopausal breast, gallbladder, stomach, liver, pancreas, kidney, ovaries, uterus, colon and rectum (colorectal) (Lauby-Secretan *et al.*, 2016).

guideline had a higher risk of breast cancer across all WC and BMI groups, with some evidence of dose–response associations (online Supplementary Table 10).

We found statistically significant three-way interaction effects between smoking status, alcohol consumption and adiposity

markers for most outcomes, for example, for alcohol-related cancer and total cancer ( $P < 0.05$  for all adiposity markers) (online Supplementary Table 11). The joint association analysis between alcohol consumption and smoking with alcohol-related cancer incidence showed that current and previous alcohol



**Fig. 3.** Joint associations between alcohol consumption and BMI with cancer incidence ( $n$  399 575). Cox proportional hazard model. Never drinker | Normal weight is the referent group. Model is adjusted for baseline age, sex, smoking status, dietary pattern score (determined by higher consumption of fruit, vegetables, and fish and lower consumption of processed meats and red meats (Rutten-Jacobs *et al.*, 2018)), sleep duration (h/night), education, Townsend Deprivation Index, physical activity ((MET)-h/week) and chronic diseases (major CVD (ICD-10 codes I00 to I99), Type 2 diabetes (ICD-10 codes E11.0 to E11.9 and E12) and dyslipidaemia (ICD-10 codes E78.0–E78.6) diagnosed by a doctor and hospital admission records and self-reported CVD and type 2 diabetes). BMI = Weight (kg)/height ( $m^2$ ). WHO classification: normal weight (18.5–24.9 kg/ $m^2$ ), overweight and obese ( $\geq$  25.0 kg/ $m^2$ ). NW: normal weight; OW: overweight; OB: obese. Alcohol consumption categories are based on the average weekly intake of standard drinks relative to UK guidelines. In the UK, one standard drink equals to 8 g of pure alcohol. Within guidelines:  $\leq$  14 units/week; above guidelines:  $>$  14 units/week. Alcohol-related cancer according to the narrow definition included oral cavity, throat, larynx, oesophagus, liver, colorectal, stomach and female breast (IARC, 2014). Obesity-related cancer included meningioma, multiple myeloma, adenocarcinoma of the oesophagus, and cancers of the thyroid, postmenopausal breast, gallbladder, stomach, liver, pancreas, kidney, ovaries, uterus, colon and rectum (colorectal) (Lauby-Secretan *et al.*, 2016).

consumption was associated with higher risk of alcohol-related cancer among previous and current smokers, but not never smokers (online Supplementary Table 12).

## Discussion

Our study is the first investigation into the joint association of alcohol consumption and multi-indicator adiposity with exposure-specific cancer incidence outcomes. We found that higher

levels of adiposity modestly amplified the deleterious association of alcohol on cancer. These synergistic effects were more pronounced for BF %. We also showed that regardless of alcohol consumption status, higher adiposity levels increased the risk of obesity-related cancer.

Despite a weak independent association of alcohol consumption and cancer outcomes, we found some evidence of the deleterious effect of the joint association with higher adiposity. Across all markers of adiposity, above guideline drinkers who



were in the top two adiposity groups had a higher cancer risk. The literature on the joint association of alcohol consumption and adiposity with cancer is limited to isolated cancer sites, such as liver cancer<sup>(20,41)</sup>, breast cancer<sup>(42)</sup> and colorectal cancer<sup>(21)</sup>. Marrero *et al.*<sup>(41)</sup> and Loomba *et al.*<sup>(20)</sup> showed that alcohol and obesity synergistically increased the risk of hepatocellular carcinoma. While, Miller *et al.*<sup>(42)</sup> found ecological evidence linking obesity and alcohol consumption with breast cancer. In a case-control study of Zhao *et al.*<sup>(21)</sup>, the effect of alcohol consumption was associated with a higher risk of colorectal cancer only in the presence of obesity. Although previous studies suggested that alcohol consumption may independently increase the risk of certain cancers<sup>(6,15,43–45)</sup>, our study showed a higher risk of cancer only among above guideline drinkers with excess adiposity. While excess adiposity was usually considered as a potential confounder in previous studies investigating alcohol consumption and cancer risk<sup>(6,45)</sup>, our analyses examining how adiposity modified the effects of alcohol consumption on cancer risk offers more nuanced information. Our results, which reconcile several limitations in the literature, provide impetus for assessing interactions between alcohol and adiposity in future observational studies.

The elevated risk of alcohol-related cancers was mostly observed in participants with excess adiposity, suggesting a synergistic effect between these two modifiable risk factors. Such a synergistic effect can be explained by common mechanistic pathways of excess adiposity and alcohol consumption involved in carcinogenesis. In the case of liver cancer, for example, both obesity and alcohol consumption could lead to oxidative stress and liver injury via multiple metabolic pathways, including cytochrome P450 2E1 induction, free radical generation, lipid peroxidation, TNF- $\alpha$  production and increased transcription of pro-inflammatory mediators<sup>(46–48)</sup>. Additionally, our analyses on the joint association between alcohol consumption and adiposity markers with risk of individual alcohol-related cancer showed that the risk of breast cancer increased with elevated WC and BMI in a dose-response manner among alcohol drinkers, indicating a possible synergistic effect between alcohol consumption and adiposity. Alcohol consumption and obesity share common biological mechanisms in breast carcinogenesis through circulating sex hormone levels such as oestrogen and sex hormone-binding globulin<sup>(49)</sup>. The biological mechanisms explaining the joint effects of alcohol consumption and adiposity on cancer risk we have found require further investigation.

Our study showed that BMI has a certain value for assessing cancer risk, but it may not be the most suitable adiposity marker. Because BMI is an indirect measure of adiposity and does not differentiate between body fat and lean body mass, nor does it specify the location of adiposity<sup>(50)</sup>, WC is often used as a surrogate marker of body fat distribution. Although WC and BMI are strongly correlated with general adiposity, WC is a better predictor of visceral adipose tissue<sup>(51)</sup>. Excess visceral adipose tissue involves the metabolic pathways of systemic inflammation, insulin resistance and the activation of the insulin-like growth factor system, leading to a pro-tumourigenic microenvironment that promotes cancer development<sup>(52,53)</sup>. Previous studies on different cancer sites showed that WC and BF % had better discriminatory power than BMI in cancer risk<sup>(54–57)</sup>.

Previous study on the association between intentional weight change and obesity-related cancer incidence in the Women's Health Initiative Observational Study demonstrated that intentional weight loss or WC reduction was associated with lower risk of obesity-related cancers<sup>(58)</sup>. A meta-analysis of nine case-control studies found that 5 years of alcohol cessation was associated with a reduction of 15% in risk of laryngeal and pharyngeal cancers<sup>(59)</sup>. Our findings provide novel information to further develop alcohol consumption and overweight and obesity management guidelines as well as emphasise how alcohol consumption guidelines and clinical advice may need to consider upward trends of obesity and overweight prevalence. This body of evidence suggesting an association between excess adiposity and alcohol consumption with many cancers substantiates the potential value of reducing alcohol consumption and weight loss as a method of cancer risk reduction.

Alcohol consumption and smoking are both biologically plausible tumour-promoting lifestyle risk factors<sup>(40)</sup>. Previous research showed that alcohol drinkers and smokers have greater risk of cancer incidence than never drinkers and smokers, indicating possible synergistic effects<sup>(60,61)</sup>. We also found that previous and current smokers who currently drink alcohol or stopped drinking have higher risk of alcohol-related cancer. As healthy lifestyle factors can have a synergistic effect and offer substantial advantages over a single factor<sup>(62)</sup>, the association between adiposity, alcohol consumption and smoking with cancer risk merits further investigation.

### Strengths and limitations

This study has several strengths, including the large longitudinal sample and hard end points (hospital admission and cancer registry). We were able to provide detailed exposure-specific outcomes (alcohol- and obesity-related cancers as well as their combinations). We were able to adjust for extensive covariates such as diet, illness and socio-economic status. Measurement of adiposity markers by trained staff using standardised techniques minimised the chance of measurement error and misclassification. We also had detailed information on drinking volume. The study has some potential limitations. Firstly, we relied on self-reported alcohol consumption which may lead to underreporting and consequently reporting biases. Still, self-reported alcohol consumption measures have demonstrated adequate reliability and validity in previous studies<sup>(63)</sup>. Additionally, we had no information on when previous drinkers stopped drinking, nor the duration, quantity or frequency of their alcohol consumption before they stopped drinking. Previous drinkers may have given up alcohol consumption due to the occurrence of health conditions, some of which may be associated with future risk of cancer and other health outcomes. This has been referred to as the 'sick-quitter effect'<sup>(64)</sup> and could result in non-drinkers appearing to have higher cancer risk in comparison with light and moderate drinkers. We addressed this issue by using never drinkers as the referent group for alcohol consumption rather than using all non-drinkers combined. Residual confounding is also possible despite a comprehensive adjustment scheme. Although we used data from cancer registries, we cannot exclude misclassification for cancer-specific sites or uncommon cancers. In addition,



we grouped all the known cancers related to alcohol and obesity which may result in missing cancer site-specific effects. The UK Biobank has very low response rate (5.5%) and may be prone to healthy volunteer selection bias. However, Stamatakis *et al.*<sup>(65)</sup> recently showed that poor representativeness does not affect materially the prospective association of alcohol with cancer risk.

## Conclusion

We found some evidence that excess adiposity may exacerbate the harmful effect of alcohol on cancer risk. Our study adds important evidence to understanding the joint role of adiposity markers and alcohol consumption in potentially leading to higher cancer incidence and supports combined alcohol consumption and adiposity reduction measures as clinical and public health priorities aimed at lowering cancer risk.

## Acknowledgements

This research has been conducted using the UK Biobank Resource, a major biomedical database, under Application Number 25813). The authors would like to thank the participants and professionals contributing to the UK Biobank study. Elif Inan-Eroglu had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This work was supported by a National Health and Medical Research Council Investigator Grant (APP1194510).

The authors' contributions were as follows: E. S. and E. I. E. contributed to conception and design of the study; E. I. E. performed statistical analyses with guidance from B. H. and E. S.; E. I. E. drafted the initial manuscript; E. S., B. H., N. N. and P. S. provided critical revisions of the manuscript. All authors read and approved the final manuscript.

The authors have no conflicts of interest to declare.

## Supplementary material

For supplementary material/s referred to in this article, please visit <https://doi.org/10.1017/S0007114522003464>

## References

- World Health Organization (2021) Cancer Fact Sheet. <https://www.who.int/news-room/fact-sheets/detail/cancer>. (accessed February 2022).
- Stein CJ & Colditz GA (2004) Modifiable risk factors for cancer. *Br J Cancer* **90**, 299–303.
- Emmons KM & Colditz GA (2017) Realizing the potential of cancer prevention – the role of implementation science. *N Engl J Med* **376**, 986–990.
- Kerr J, Anderson C & Lippman SM (2017) Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. *Lancet Oncol* **18**, e457–e471.
- World Health Organization & International Agency for Research on Cancer (1988) *Alcohol Drinking: Summary of Data Reported and Evaluation*. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC.
- Bagnardi V, Rota M, Botteri E, *et al.* (2015) Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. *Br J Cancer* **112**, 580.
- Nelson DE, Jarman DW, Rehm J, *et al.* (2013) Alcohol-attributable cancer deaths and years of potential life lost in the United States. *Am J Public Health* **103**, 641–648.
- Rumgay H, Shield K, Charvat, *et al.* (2021) Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. *Lancet Oncol* **22**, 1071–1080.
- Griswold MG, Fullman N, Hawley C, *et al.* (2018) Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet* **392**, 1015–1035.
- Dawson DA, Goldstein RB, Saha TD, *et al.* (2015) Changes in alcohol consumption: United States, 2001–2002 to 2012–2013. *Drug Alcohol Depend* **148**, 56–61.
- Australian Institute of Health and Welfare (2021) Alcohol, Tobacco & Other Drugs in Australia. <https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/drug-types/alcohol> (accessed February 2022).
- NCD Risk Factor Collaboration (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* **387**, 1377–1396.
- Ng M, Fleming T, Robinson M, *et al.* (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. *Lancet* **384**, 766–781.
- Lauby-Secretan B, Scoccianti C, Loomis D, *et al.* (2016) Body fatness and cancer—viewpoint of the IARC working group. *N Engl J Med* **375**, 794–798.
- de Menezes RF, Bergmann A & Thuler LCS (2013) Alcohol consumption and risk of cancer: a systematic literature review. *Asian Pac J Cancer Prev* **14**, 4965–4972.
- Zhao J, Stockwell T, Roemer A, *et al.* (2016) Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. *BMC Cancer* **16**, 1–13.
- Ma Y, Yang Y, Wang F, *et al.* (2013) Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLOS ONE* **8**, e53916.
- Renahan AG, Tyson M, Egger M, *et al.* (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* **371**, 569–578.
- An SY, Kim SY, Oh DJ, *et al.* (2020) Obesity is positively related and tobacco smoking and alcohol consumption are negatively related to an increased risk of thyroid cancer. *Sci Rep* **10**, 1–9.
- Loomba R, Yang HI, Su J, *et al.* (2010) Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. *Clin Gastroenterol Hepatol* **8**, 891–898.
- Zhao J, Zhu Y, Wang PP, *et al.* (2012) Interaction between alcohol drinking and obesity in relation to colorectal cancer risk: a case-control study in Newfoundland and Labrador, Canada. *BMC Public Health* **12**, 1–9.
- Sudlow C, Gallacher J, Allen N, *et al.* (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779.
- Inan-Eroglu E, Huang BH, Ahmadi MN, *et al.* (2022) Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank. *Eur J Clin Nutr* **76**, 74–83.
- Department of Health (2016) *Alcohol Guidelines Review – Report from the Guidelines Development Group to the UK Chief Medical Officers*. London: Department of Health.
- Powell L, Feng Y, Duncan MJ, *et al.* (2020) Does a physically active lifestyle attenuate the association between alcohol



- consumption and mortality risk? Findings from the UK biobank. *Prev Med* **130**, 105901.
26. World Health Organization (2011) *Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8–11 December 2008*. Geneva: World Health Organization.
27. World Health Organization (1978) *International Classification of Diseases*. Geneva: World Health Organization.
28. World Health Organization (1992). *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. Geneva: World Health Organization.
29. Feng Y, Powell L, Vassallo AJ, *et al.* (2020) Does adequate physical activity attenuate the associations of alcohol and alcohol-related cancer mortality? A pooled study of 54,686 British adults. *Cancer Epidemiol* **147**, 2754–2763.
30. Corrao G, Bagnardi V, Zamboni A, *et al.* (2004) A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med* **38**, 613–619.
31. Boffetta P & Hashibe M (2006) Alcohol and cancer. *Lancet Oncol* **7**, 149–156.
32. Korte JE, Brennan P, Henley SJ, *et al.* (2002) Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. *Am J Epidemiol* **155**, 496–506.
33. International Agency for Research on Cancer (2018) IARC Monographs of Carcinogenic Hazards to Humans and Handbooks of Cancer Prevention: IARC. [https://monographs.iarc.fr/wp-content/uploads/2019/01/OrganSitePoster\\_PlusHandbooks.17012019.pdf](https://monographs.iarc.fr/wp-content/uploads/2019/01/OrganSitePoster_PlusHandbooks.17012019.pdf) (accessed February 2022).
34. Rutten-Jacobs LC, Larsson SC, Malik R, *et al.* (2018) Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants. *BMJ* **363**, k4168.
35. National Health Service (2019) 8 Tips for Healthy Eating. <https://www.nhs.uk/live-well/eat-well/eight-tips-for-healthy-eating/> (accessed February 2022).
36. Buttriss JL (2016) The eatwell guide refreshed. *Nutr Bull* **41**, 135–141.
37. Craig CL, Marshall AL, Sjöström M, *et al.* (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* **35**, 1381–1395.
38. Townsend P, Phillimore P & Beattie A (1998) *Health and Deprivation: Inequality and the North*. London: Croom Helm Ltd.
39. Dudley WN, Wickham R & Coombs N (2016) An introduction to survival statistics: Kaplan-Meier analysis. *JADPRO* **7**, 91.
40. Larsson SC, Carter P, Kar S, *et al.* (2020) Smoking, alcohol consumption, and cancer: a Mendelian randomisation study in UK Biobank and international genetic consortia participants. *PLoS Med* **17**, e1003178.
41. Marrero JA, Fontana RJ, Fu S, *et al.* (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. *J Hepatol* **42**, 218–224.
42. Miller ER, Wilson C, Chapman J, *et al.* (2018) Connecting the dots between breast cancer, obesity and alcohol consumption in middle-aged women: ecological and case control studies. *BMC Public Health* **18**, 1–14.
43. Rehm J, Soerjomataram I, Ferreira-Borges C, *et al.* (2019) Does alcohol use affect cancer risk?. *Curr Nutr Rep* **8**, 222–229.
44. Sarich P, Canfell K, Egger S, *et al.* (2021) Alcohol consumption, drinking patterns and cancer incidence in an Australian cohort of 226,162 participants aged 45 years and over. *Br J Cancer* **124**, 513–523.
45. Smyth A, Teo KK, Rangarajan S, *et al.* (2015) Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. *Lancet* **386**, 1945–1954.
46. Purohit V & Brenner DA (2006) Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. *Hepatology* **43**, 872–878.
47. Siegmund SV & Brenner DA (2005) Molecular pathogenesis of alcohol-induced hepatic fibrosis. *Alcohol Clin Exp Res* **29**, 102S–109S.
48. Naugler WE & Karin M (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol Med* **14**, 109–119.
49. Shin A, Sandin S, Lof M, *et al.* (2015) Alcohol consumption, body mass index and breast cancer risk by hormone receptor status: women's lifestyle and health study. *BMC Cancer* **15**, 1–6.
50. Bandera EV, Fay SH, Giovannucci E, *et al.* (2016) The use and interpretation of anthropometric measures in cancer epidemiology: a perspective from the world cancer research fund international continuous update project. *Int J Cancer* **139**, 2391–2397.
51. Shen W, Punyanitya M, Wang Z, *et al.* (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol* **97**, 2333–2338.
52. Donohoe CL, Doyle SL & Reynolds JV (2011) Visceral adiposity, insulin resistance and cancer risk. *Diabetol Metab Syndr* **3**, 1–13.
53. Silveira EA, Kliemann N, Noll M, *et al.* (2021) Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence. *Obes Rev* **22**, e13088.
54. Wei L, Li N, Wang G, *et al.* (2018) Waist circumference might be a predictor of primary liver cancer: a population-based cohort study. *Front Oncol* **8**, 607.
55. Moore LL, Bradlee ML, Singer MR, *et al.* (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham study adults. *IJO* **28**, 559–567.
56. Si S, Tewara MA, Ji X, *et al.* (2020) Body surface area, height, and body fat percentage as more sensitive risk factors of cancer and cardiovascular disease. *Cancer Med* **9**, 4433–4446.
57. Lee KR, Seo MH, Do Han K, *et al.* (2018) Waist circumference and risk of 23 site-specific cancers: a population-based cohort study of Korean adults. *Br J Cancer* **119**, 1018–1027.
58. Luo J, Hendryx M, Manson JE, *et al.* (2019) Intentional weight loss and obesity-related cancer risk. *JNCI Cancer Spectr* **3**, pkz054.
59. Ahmad Kiadaliri A, Jarl J, Gavrilidis G, *et al.* (2013) Alcohol drinking cessation and the risk of laryngeal and pharyngeal cancers: a systematic review and meta-analysis. *PLOS ONE* **8**, e58158.
60. Hashibe M, Brennan P, Chuang SC, *et al.* (2009) Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. *Cancer Epidemiol Biomarkers Prev* **18**, 541–550.
61. Turati F, Garavello W, Tramacere I, *et al.* (2013) A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. *Alcohol Alcohol* **48**, 107–118.
62. Katzke VA, Kaaks R & Kühn T (2015) Lifestyle and cancer risk. *Cancer J* **21**, 104–110.
63. Del Boca FK & Darkes J (2003) The validity of self-reports of alcohol consumption: state of the science and challenges for research. *Addiction* **98**, 1–12.
64. Sarich P, Canfell K, Banks E, *et al.* (2019) A prospective study of health conditions related to alcohol consumption cessation among 97,852 drinkers aged 45 and over in Australia. *Alcohol Clin Exp Res* **43**, 710–721.
65. Stamatakis E, Owen KB, Shepherd L, *et al.* (2021) Is cohort representativeness passé? Poststratified associations of lifestyle risk factors with mortality in the UK Biobank. *Epidemiology* **32**, 179.